|
|
| Model Number |
TG0705509 |
| Medical Device Problem Code |
Fluid/Blood Leak (1250)
|
| Health Effect - Clinical Code |
No Clinical Signs, Symptoms or Conditions (4582)
|
| Date of Event |
03/19/2021
|
|
Type of Reportable Event
|
Malfunction
|
|
Additional Manufacturer Narrative
|
|
Conclusion not yet available, evaluation in process.A follow-up will be submitted as soon as the investigation is complete.
|
| |
|
Event or Problem Description
|
|
It was reported that the orange anti-return valve introducer does not work; resulting in blood reflux.The person or patient involved is showing an increase in blood loss.Procedure completed with another device.No additional information available at this time.
|
| |
|
Additional Manufacturer Narrative
|
|
Changed aptus endosystems steerable sheath to tourguide steerable sheath.The device was used in treatment.The device history records were reviewed to confirm that the device passed all applicable in-process and final inspections.The device was not returned for analysis, therefore, the exact cause of the product issue cannot be determined and the clinical observation could not be confirmed.However, following controls are in place to mitigate the reported product issue.Per qa procedure (destino steerable guiding sheath in-process and final inspection) leak test: perform leak test according to procedures based on available leak tester.The leak test is performed by manufacturing personnel and is observed by quality assurance personnel.This procedure is performed 100%.Per ifu: use the sideport, located at the handle, to inject contrast solution or flush the steerable sheath.The steerable sheath must be thoroughly flushed with either saline or heparinized saline and free of air prior to use to avoid air embolism to the patient.Wet the dilator shaft with sterile saline solution prior to insertion through the hemostatic valve.Note: any device/component inserted through the hemostatic valve of the sheath should be wet and placed through the center of the valve to prevent tearing of the seal and leakage.No further follow-up action required.Based on the investigation, a capa is not required as findings did not identify a design, labeling or manufacturing non-conformity.The event will be re-evaluated if additional information becomes available.Oscor will continue to monitor this event type and risk.Oscor inc.Is submitting the above report to comply with 21 cfr part 803, the medical device reporting regulation.The report is based upon information obtained by oscor inc.Which the company may not have been able to investigate or verify prior to the date the report was required by fda.This report does not constitute an admission that the device, oscor inc., or its employees, caused or contributed to the event described in this report.Nor does this report reflect a conclusion by fda, oscor inc., or its employees, that the report constitutes an admission that the device, oscor inc., or its employees caused or contributed to the event described in this report.
|
| |
|
Additional Manufacturer Narrative
|
|
The following sections were updated in follow-up 2.B3, b4, g3, g6, h2, h10, h11.Correction b3: corrected event date from 03/09/2021 to 03/19/2021.Oscor inc.Is submitting the above report to comply with 21 cfr part 803, the medical device reporting regulation.The report is based upon information obtained by oscor inc.Which the company may not have been able to investigate or verify prior to the date the report was required by fda.This report does not constitute an admission that the device, oscor inc., or its employees, caused or contributed to the event described in this report.Nor does this report reflect a conclusion by fda, oscor inc., or its employees, that the report constitutes an admission that the device, oscor inc., or its employees caused or contributed to the event described in this report.
|
| |
|
Search Alerts/Recalls
|
|
|